Last edition
News about "hematologic malignancies"
PharmaEssentia Secures Taiwan Approval for BESREMi in Essential Thrombocythemia
PharmaEssentia has received Taiwan approval for BESREMi as the first globally approved treatment for Essential Thrombocythemia (ET), marking the first new approved therapy for the disease in nearly 30 years.
Hematologic Malignancies | 11/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members